Francesca Crawford - Chief Executive Officer
Fran Crawford has been closely involved in the growth of several life science businesses including Altacor, Sirus Pharmaceuticals Ltd, Spirogen Ltd and Ethical Holdings PLC. She has participated in M&A and in creating exits for the benefit of shareholders and investors. Fran is a PhD clinical pharmacologist who, following two post-doctoral posts entered the pharmaceutical industry in clinical research with Ethical Holdings. She has an extensive record of product development and regulatory approvals (formulation to market) in Europe and the US as well as in- and out-licensing. Holding senior posts in several start-up businesses she has built IP portfolios to add value and protection to product pipelines. More recently she has been responsible for growing hospital and retail sales teams to commercialise products in a Specialty Pharma setting.
Dean Slagel - Managing Director, Esperante VenturesDean Slagel has 23 years of biotechnology and pharmaceutical industry experience and an MBA from ENPC Paris. Starting in international marketing at Tillotts Pharma in Switzerland, he spent 10 years with the Ferring Group in regional operations management and global business development management based in the UK, Denmark and France. He has managed Esperante since 2004, during which time he has been responsible for building a 21 company investment portfolio in the USA, UK, France, Israel and Switzerland to date. During this period, Esperante has completed two successful exits (Thiakis and Pinnacle Biologics) and one IPO (Cara). Mr Slagel is currently a Director on the Boards of Altacor, Atox Bio, Cara Therapeutics, Canbex Therapeutics and Urosens.